Company: ATRA
Filing Date: 2025-05-12
Form Type: 8-K
Source: 0000950170-25-069198
Chunk: 0

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-05-12
Form: 8-K
Item: Item 2.05
Chunk 0
---
Item 2.05 Costs Associated with Exit or Disposal Activities.

On May 12, 2025, Atara Biotherapeutics, Inc. (the “ Company”) announced a reduction in its workforce that will impact approximately 30% of its current employees, retaining approximately 23 employees essential to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by August 2025. The Company expects to recognize approximately $1.4 million for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash charges. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction. Additional details will be provided in the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                        ATARA BIOTHERAPEUTICS, INC.                               
  Date:      May 12, 2025      By:      /s/ AnhCo Thieu Nguyen                                    
                                        AnhCo Thieu Nguyen